Cantor Fitzgerald Initiates Coverage of Opus Genetics (IRD) with Overweight Recommendation

Cantor Fitzgerald initiated coverage of Opus Genetics (NasdaqCM: IRD) on March 30, 2026 with an Overweight rating and a price forecast implying 123.66% upside. The initiation represents a bullish analyst view that could drive stock-specific buying interest, though the impact is likely constrained to company-level moves rather than broader sector or market shifts.

Analysis

Cantor Fitzgerald initiated coverage of Opus Genetics (NasdaqCM: IRD) on March 30, 2026 with an Overweight rating and a price forecast implying 123.66% upside. The initiation represents a bullish analyst view that could drive stock-specific buying interest, though the impact is likely constrained to company-level moves rather than broader sector or market shifts.